The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Angelo Zino, Senior Vice President and Technology Equity Research Analyst at CFRA, breaks down Big Tech earnings, AI spending, and what's next for the Mag 7.
Big Tech is pouring billions into AI. Ray Wang, CEO of Constellation Research, explains what Meta and Microsoft's earnings reveal about those investments.
Morningstar equity analyst Nicolas Owens explains Boeing's latest earnings, deliveries, rising fuel costs, and what they mean for airlines and investors.
